X

AbbVie (ABBV) AbbVie Announces Positive Topline Results from a Phase 1 Multiple Ascending Dose Study of ABBV-295, a Long-Acting Amylin Analog, in Adults

AbbVie (NYSE: ABBV) FY 2026 Other Release

Newsdesk: